On yesterday's call, Amarin shared a few data points of Vascepa's growth post Reduce-IT results that offered a glimpse of the revenue momentum, and "may be a forbearer of what is to come," H.C. Wainwright analyst Andrew Fein tells investors in a research note. The analyst highlights the 32%-33% prescription increase in the Q4 compared to the same period in 2017. Further, he expects Amarin to promote Vascepa with a greater degree of freedom that should further accelerate the adoption. Fein reiterates a Buy rating on Amarin with a $51 price target.

Amarin Corporation announced shareholder approval of all proposed resolutions specified at its 2024 Annual General Meeting. Importantly, shareholders approved each of the two proposals required for the Company to proceed with its previously announced intent to pursue a share repurchase program of up to $50 million. This permits the Company to request U.K. High Court approval, as required under U.K. company law, and if approved by the U.K. High Court, commence the share repurchase program by the end of the second quarter of 2024. As part of the Annual General Meeting, shareholders also approved the following resolutions: Re-elected Mr. Patrick Holt, Mr. Louis Sterling III and Ms. Patrice Bonfiglio as directors of the Company; Approved the compensation of the Company's "named executive officers" as described in full in the "Executive Compensation Discussion and Analysis" section of the Company's definitive proxy statement; Approved the appointment of Ernst & Young LLP as auditors of the Company until the conclusion of the next general meeting; Approved the proposed amendment to the Company's 2020 Stock Incentive Plan; Authorized and approved the amended and restated articles of association to require all directors to retire and seek re-election at each annual general meeting of the Company.